MX2007012667A - Tratamiento de la enfermedad inflamatoria intestinal (eii). - Google Patents

Info

Publication number

MX2007012667A

MX2007012667A MX2007012667A MX2007012667A MX2007012667A MX 2007012667 A MX2007012667 A MX 2007012667A MX 2007012667 A MX2007012667 A MX 2007012667A MX 2007012667 A MX2007012667 A MX 2007012667A MX 2007012667 A MX2007012667 A MX 2007012667A

Authority

MX

Mexico

Prior art keywords

disease

cells

ibd

antiquake

human

Prior art date

2005-04-15

Links

• Espacenet
• Global Dossier
• Discuss

• 208000022559 Inflammatory bowel disease Diseases 0.000 title claims abstract description 73
• 238000000034 method Methods 0.000 title claims description 121
• 206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 76
• 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 76
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims abstract description 68
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims abstract description 68
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 121
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 81
• 201000010099 disease Diseases 0.000 claims description 80
• 239000003814 drug Substances 0.000 claims description 69
• 229940079593 drug Drugs 0.000 claims description 54
• 230000000694 effects Effects 0.000 claims description 32
• 230000004044 response Effects 0.000 claims description 27
• 206010011224 Cough Diseases 0.000 claims description 25
• 210000004877 mucosa Anatomy 0.000 claims description 20
• 229940124624 oral corticosteroid Drugs 0.000 claims description 19
• 208000023275 Autoimmune disease Diseases 0.000 claims description 15
• 238000001990 intravenous administration Methods 0.000 claims description 14
• 208000011231 Crohn disease Diseases 0.000 claims description 13
• 206010028980 Neoplasm Diseases 0.000 claims description 13
• 206010038063 Rectal haemorrhage Diseases 0.000 claims description 12
• 230000000968 intestinal effect Effects 0.000 claims description 12
• 238000002579 sigmoidoscopy Methods 0.000 claims description 12
• 230000000112 colonic effect Effects 0.000 claims description 10
• 108010029485 Protein Isoforms Proteins 0.000 claims description 7
• 102000001708 Protein Isoforms Human genes 0.000 claims description 7
• 230000001086 cytosolic effect Effects 0.000 claims description 7
• 230000002829 reductive effect Effects 0.000 claims description 7
• 201000011510 cancer Diseases 0.000 claims description 6
• 102000005937 Tropomyosin Human genes 0.000 claims description 4
• 108010030743 Tropomyosin Proteins 0.000 claims description 4
• 230000001093 anti-cancer Effects 0.000 claims description 3
• 230000000703 anti-shock Effects 0.000 claims description 2
• 230000036210 malignancy Effects 0.000 claims description 2
• 238000011282 treatment Methods 0.000 abstract description 79
• 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
• 239000005557 antagonist Substances 0.000 description 104
• 239000000427 antigen Substances 0.000 description 82
• 108091007433 antigens Proteins 0.000 description 80
• 102000036639 antigens Human genes 0.000 description 80
• 210000004027 cell Anatomy 0.000 description 69
• 239000012634 fragment Substances 0.000 description 52
• 238000006467 substitution reaction Methods 0.000 description 46
• 125000003275 alpha amino acid group Chemical group 0.000 description 38
• 108090000623 proteins and genes Proteins 0.000 description 37
• 108090000765 processed proteins & peptides Proteins 0.000 description 34
• 108060003951 Immunoglobulin Proteins 0.000 description 32
• 102000018358 immunoglobulin Human genes 0.000 description 32
• 235000001014 amino acid Nutrition 0.000 description 29
• 238000002560 therapeutic procedure Methods 0.000 description 26
• 210000004369 blood Anatomy 0.000 description 25
• 239000008280 blood Substances 0.000 description 25
• 239000000203 mixture Substances 0.000 description 24
• 239000003795 chemical substances by application Substances 0.000 description 23
• 102000005962 receptors Human genes 0.000 description 22
• 108020003175 receptors Proteins 0.000 description 22
• 238000004519 manufacturing process Methods 0.000 description 21
• 102000004196 processed proteins & peptides Human genes 0.000 description 21
• 235000018102 proteins Nutrition 0.000 description 21
• 102000004169 proteins and genes Human genes 0.000 description 21
• 230000009467 reduction Effects 0.000 description 21
• 229920001184 polypeptide Polymers 0.000 description 18
• 206010003246 arthritis Diseases 0.000 description 17
• 238000001802 infusion Methods 0.000 description 17
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 16
• 241000219061 Rheum Species 0.000 description 16
• 229940024606 amino acid Drugs 0.000 description 16
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 16
• 230000006870 function Effects 0.000 description 16
• 239000000126 substance Substances 0.000 description 16
• 150000001413 amino acids Chemical class 0.000 description 15
• 229940127089 cytotoxic agent Drugs 0.000 description 15
• 238000009472 formulation Methods 0.000 description 15
• -1 cyclophosphamide Chemical compound 0.000 description 14
• 241000699670 Mus sp. Species 0.000 description 13
• 239000002253 acid Substances 0.000 description 13
• 208000015181 infectious disease Diseases 0.000 description 13
• 150000003431 steroids Chemical class 0.000 description 13
• 208000024891 symptom Diseases 0.000 description 13
• 241001465754 Metazoa Species 0.000 description 12
• 230000001419 dependent effect Effects 0.000 description 12
• 239000012636 effector Substances 0.000 description 12
• 102000004127 Cytokines Human genes 0.000 description 11
• 108090000695 Cytokines Proteins 0.000 description 11
• 150000001720 carbohydrates Chemical group 0.000 description 11
• 239000002458 cell surface marker Substances 0.000 description 11
• 210000001072 colon Anatomy 0.000 description 11
• 239000003246 corticosteroid Substances 0.000 description 11
• 229960001334 corticosteroids Drugs 0.000 description 11
• 239000000047 product Substances 0.000 description 11
• 229960004641 rituximab Drugs 0.000 description 11
• 150000003839 salts Chemical class 0.000 description 11
• 210000002966 serum Anatomy 0.000 description 11
• 230000001225 therapeutic effect Effects 0.000 description 11
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 10
• 102100024952 Protein CBFA2T1 Human genes 0.000 description 10
• 239000003112 inhibitor Substances 0.000 description 10
• 229960000485 methotrexate Drugs 0.000 description 10
• 150000003384 small molecules Chemical class 0.000 description 10
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 9
• 108020004414 DNA Proteins 0.000 description 9
• 108010008165 Etanercept Proteins 0.000 description 9
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 9
• 230000004071 biological effect Effects 0.000 description 9
• 230000001684 chronic effect Effects 0.000 description 9
• 206010009887 colitis Diseases 0.000 description 9
• 239000002254 cytotoxic agent Substances 0.000 description 9
• 231100000599 cytotoxic agent Toxicity 0.000 description 9
• 230000003013 cytotoxicity Effects 0.000 description 9
• 231100000135 cytotoxicity Toxicity 0.000 description 9
• 230000004927 fusion Effects 0.000 description 9
• 229940088597 hormone Drugs 0.000 description 9
• 239000005556 hormone Substances 0.000 description 9
• 238000001727 in vivo Methods 0.000 description 9
• 210000000265 leukocyte Anatomy 0.000 description 9
• 210000004698 lymphocyte Anatomy 0.000 description 9
• 229960004618 prednisone Drugs 0.000 description 9
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 9
• 210000000664 rectum Anatomy 0.000 description 9
• 239000013589 supplement Substances 0.000 description 9
• XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 8
• 125000000539 amino acid group Chemical group 0.000 description 8
• 239000003242 anti bacterial agent Substances 0.000 description 8
• 238000013459 approach Methods 0.000 description 8
• 230000015572 biosynthetic process Effects 0.000 description 8
• 230000001472 cytotoxic effect Effects 0.000 description 8
• 238000005516 engineering process Methods 0.000 description 8
• 230000014509 gene expression Effects 0.000 description 8
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
• 230000004048 modification Effects 0.000 description 8
• 238000012986 modification Methods 0.000 description 8
• 229960004866 mycophenolate mofetil Drugs 0.000 description 8
• 229940068196 placebo Drugs 0.000 description 8
• 239000000902 placebo Substances 0.000 description 8
• 230000008569 process Effects 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 238000007920 subcutaneous administration Methods 0.000 description 8
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 7
• 108010087819 Fc receptors Proteins 0.000 description 7
• 102000009109 Fc receptors Human genes 0.000 description 7
• 206010035226 Plasma cell myeloma Diseases 0.000 description 7
• 230000004075 alteration Effects 0.000 description 7
• 229940088710 antibiotic agent Drugs 0.000 description 7
• 239000002246 antineoplastic agent Substances 0.000 description 7
• 235000014633 carbohydrates Nutrition 0.000 description 7
• 238000002512 chemotherapy Methods 0.000 description 7
• 229960004397 cyclophosphamide Drugs 0.000 description 7
• 231100000433 cytotoxic Toxicity 0.000 description 7
• 229960000403 etanercept Drugs 0.000 description 7
• 230000005713 exacerbation Effects 0.000 description 7
• 238000009541 flexible sigmoidoscopy Methods 0.000 description 7
• 210000001035 gastrointestinal tract Anatomy 0.000 description 7
• 239000003102 growth factor Substances 0.000 description 7
• 238000000338 in vitro Methods 0.000 description 7
• 229960000598 infliximab Drugs 0.000 description 7
• 238000002347 injection Methods 0.000 description 7
• 239000007924 injection Substances 0.000 description 7
• 238000003780 insertion Methods 0.000 description 7
• 230000037431 insertion Effects 0.000 description 7
• 239000003550 marker Substances 0.000 description 7
• 230000001404 mediated effect Effects 0.000 description 7
• 238000002703 mutagenesis Methods 0.000 description 7
• 231100000350 mutagenesis Toxicity 0.000 description 7
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 7
• 201000000050 myeloid neoplasm Diseases 0.000 description 7
• 210000000822 natural killer cell Anatomy 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 238000012552 review Methods 0.000 description 7
• 230000000699 topical effect Effects 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
• 229940123494 CD20 antagonist Drugs 0.000 description 6
• 108091008874 T cell receptors Proteins 0.000 description 6
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
• 210000001744 T-lymphocyte Anatomy 0.000 description 6
• 238000003556 assay Methods 0.000 description 6
• 238000001574 biopsy Methods 0.000 description 6
• 238000004113 cell culture Methods 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 230000000295 complement effect Effects 0.000 description 6
• 230000003247 decreasing effect Effects 0.000 description 6
• 230000012010 growth Effects 0.000 description 6
• 230000036541 health Effects 0.000 description 6
• 210000004408 hybridoma Anatomy 0.000 description 6
• 230000006872 improvement Effects 0.000 description 6
• 206010025135 lupus erythematosus Diseases 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
• 210000004180 plasmocyte Anatomy 0.000 description 6
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
• 238000011160 research Methods 0.000 description 6
• 210000001519 tissue Anatomy 0.000 description 6
• 229960005486 vaccine Drugs 0.000 description 6
• 238000002965 ELISA Methods 0.000 description 5
• 208000032843 Hemorrhage Diseases 0.000 description 5
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 5
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 5
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
• 239000002202 Polyethylene glycol Substances 0.000 description 5
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 5
• 230000001773 anti-convulsant effect Effects 0.000 description 5
• 239000001961 anticonvulsive agent Substances 0.000 description 5
• 230000006907 apoptotic process Effects 0.000 description 5
• 230000007812 deficiency Effects 0.000 description 5
• 229960003957 dexamethasone Drugs 0.000 description 5
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
• 238000003745 diagnosis Methods 0.000 description 5
• 230000009266 disease activity Effects 0.000 description 5
• 239000001963 growth medium Substances 0.000 description 5
• 230000001976 improved effect Effects 0.000 description 5
• 230000006698 induction Effects 0.000 description 5
• 210000002429 large intestine Anatomy 0.000 description 5
• 210000004379 membrane Anatomy 0.000 description 5
• 239000012528 membrane Substances 0.000 description 5
• 229960004584 methylprednisolone Drugs 0.000 description 5
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 5
• 210000000440 neutrophil Anatomy 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 230000002285 radioactive effect Effects 0.000 description 5
• 239000011734 sodium Substances 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• 230000002792 vascular Effects 0.000 description 5
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 4
• 206010067484 Adverse reaction Diseases 0.000 description 4
• 108010088751 Albumins Proteins 0.000 description 4
• 102000009027 Albumins Human genes 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
• 206010061218 Inflammation Diseases 0.000 description 4
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
• 208000025865 Ulcer Diseases 0.000 description 4
• 206010047115 Vasculitis Diseases 0.000 description 4
• 230000002411 adverse Effects 0.000 description 4
• 230000006838 adverse reaction Effects 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 230000000692 anti-sense effect Effects 0.000 description 4
• 229960003965 antiepileptics Drugs 0.000 description 4
• 210000000436 anus Anatomy 0.000 description 4
• 230000001588 bifunctional effect Effects 0.000 description 4
• 210000001185 bone marrow Anatomy 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 4
• 229960004630 chlorambucil Drugs 0.000 description 4
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
• 238000012321 colectomy Methods 0.000 description 4
• 229920001577 copolymer Polymers 0.000 description 4
• 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 4
• 239000003085 diluting agent Substances 0.000 description 4
• 239000000539 dimer Substances 0.000 description 4
• 229940088598 enzyme Drugs 0.000 description 4
• 150000002148 esters Chemical class 0.000 description 4
• 238000011156 evaluation Methods 0.000 description 4
• 230000013595 glycosylation Effects 0.000 description 4
• 238000006206 glycosylation reaction Methods 0.000 description 4
• 229960000890 hydrocortisone Drugs 0.000 description 4
• 230000001900 immune effect Effects 0.000 description 4
• 229940072221 immunoglobulins Drugs 0.000 description 4
• 238000009169 immunotherapy Methods 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 239000003446 ligand Substances 0.000 description 4
• 238000002483 medication Methods 0.000 description 4
• KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 4
• 229960004963 mesalazine Drugs 0.000 description 4
• 230000035772 mutation Effects 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• 239000002245 particle Substances 0.000 description 4
• 230000002035 prolonged effect Effects 0.000 description 4
• 238000011084 recovery Methods 0.000 description 4
• 210000000813 small intestine Anatomy 0.000 description 4
• 229910052708 sodium Inorganic materials 0.000 description 4
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
• 229940124292 CD20 monoclonal antibody Drugs 0.000 description 3
• 102220517543 Calcium uniporter protein, mitochondrial_S92A_mutation Human genes 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 3
• 108010072051 Glatiramer Acetate Proteins 0.000 description 3
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
• 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 3
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 3
• 108010033040 Histones Proteins 0.000 description 3
• 108010002350 Interleukin-2 Proteins 0.000 description 3
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 102220475559 Radial spoke head 1 homolog_D56A_mutation Human genes 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 3
• 241000283984 Rodentia Species 0.000 description 3
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 230000005856 abnormality Effects 0.000 description 3
• 230000003213 activating effect Effects 0.000 description 3
• 239000013543 active substance Substances 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• 150000001299 aldehydes Chemical class 0.000 description 3
• 230000002082 anti-convulsion Effects 0.000 description 3
• 229940125714 antidiarrheal agent Drugs 0.000 description 3
• 239000003793 antidiarrheal agent Substances 0.000 description 3
• 230000001363 autoimmune Effects 0.000 description 3
• 229960002170 azathioprine Drugs 0.000 description 3
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 238000002659 cell therapy Methods 0.000 description 3
• 150000001875 compounds Chemical class 0.000 description 3
• 230000021615 conjugation Effects 0.000 description 3
• 239000003431 cross linking reagent Substances 0.000 description 3
• 239000000430 cytokine receptor antagonist Substances 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 229960004679 doxorubicin Drugs 0.000 description 3
• 210000002919 epithelial cell Anatomy 0.000 description 3
• 230000007717 exclusion Effects 0.000 description 3
• 239000013604 expression vector Substances 0.000 description 3
• 229960002949 fluorouracil Drugs 0.000 description 3
• 210000004602 germ cell Anatomy 0.000 description 3
• 239000003862 glucocorticoid Substances 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 3
• 229960000681 leflunomide Drugs 0.000 description 3
• RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 3
• 210000001165 lymph node Anatomy 0.000 description 3
• 238000009115 maintenance therapy Methods 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
• 239000003094 microcapsule Substances 0.000 description 3
• 229960001156 mitoxantrone Drugs 0.000 description 3
• 239000003607 modifier Substances 0.000 description 3
• 210000004400 mucous membrane Anatomy 0.000 description 3
• 102000039446 nucleic acids Human genes 0.000 description 3
• 108020004707 nucleic acids Proteins 0.000 description 3
• 150000007523 nucleic acids Chemical class 0.000 description 3
• 230000008506 pathogenesis Effects 0.000 description 3
• 230000001717 pathogenic effect Effects 0.000 description 3
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
• 239000008194 pharmaceutical composition Substances 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• 229910052697 platinum Inorganic materials 0.000 description 3
• 230000005180 public health Effects 0.000 description 3
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 3
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
• 230000006798 recombination Effects 0.000 description 3
• 238000005215 recombination Methods 0.000 description 3
• 229940116176 remicade Drugs 0.000 description 3
• 102220241870 rs761659830 Human genes 0.000 description 3
• 210000001599 sigmoid colon Anatomy 0.000 description 3
• 229960002930 sirolimus Drugs 0.000 description 3
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
• 229940087854 solu-medrol Drugs 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 230000002269 spontaneous effect Effects 0.000 description 3
• 238000003860 storage Methods 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
• 229960005267 tositumomab Drugs 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 3
• HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
• ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 2
• BQIMPGFMMOZASS-CLZZGJSISA-N (6r,7r)-7-amino-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1CC(CO)=C(C(O)=O)N2C(=O)[C@@H](N)[C@H]21 BQIMPGFMMOZASS-CLZZGJSISA-N 0.000 description 2
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
• WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
• GANZODCWZFAEGN-UHFFFAOYSA-N 5-mercapto-2-nitro-benzoic acid Chemical compound OC(=O)C1=CC(S)=CC=C1[N+]([O-])=O GANZODCWZFAEGN-UHFFFAOYSA-N 0.000 description 2
• 208000004998 Abdominal Pain Diseases 0.000 description 2
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
• 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
• 108010082126 Alanine transaminase Proteins 0.000 description 2
• 206010002329 Aneurysm Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
• 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
• 240000007124 Brassica oleracea Species 0.000 description 2
• 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 2
• 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 2
• 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 2
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 2
• 229920001268 Cholestyramine Polymers 0.000 description 2
• 102100032768 Complement receptor type 2 Human genes 0.000 description 2
• 108091035707 Consensus sequence Proteins 0.000 description 2
• SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
• 206010012735 Diarrhoea Diseases 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
• 108700012941 GNRH1 Proteins 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• 102000001554 Hemoglobins Human genes 0.000 description 2
• 108010054147 Hemoglobins Proteins 0.000 description 2
• 208000005176 Hepatitis C Diseases 0.000 description 2
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
• 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
• 241000539428 Hybroma Species 0.000 description 2
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
• 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 102100025390 Integrin beta-2 Human genes 0.000 description 2
• 102000006992 Interferon-alpha Human genes 0.000 description 2
• 108010047761 Interferon-alpha Proteins 0.000 description 2
• 206010022653 Intestinal haemorrhages Diseases 0.000 description 2
• 102100020880 Kit ligand Human genes 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
• 102000009151 Luteinizing Hormone Human genes 0.000 description 2
• 108010073521 Luteinizing Hormone Proteins 0.000 description 2
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
• 241000282567 Macaca fascicularis Species 0.000 description 2
• 201000005505 Measles Diseases 0.000 description 2
• ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 2
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
• 102220556084 Myeloid cell surface antigen CD33_N100A_mutation Human genes 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 241000599931 Paris quadrifolia Species 0.000 description 2
• 201000011152 Pemphigus Diseases 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 206010037660 Pyrexia Diseases 0.000 description 2
• IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
• 108010039445 Stem Cell Factor Proteins 0.000 description 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 102000011923 Thyrotropin Human genes 0.000 description 2
• 108010061174 Thyrotropin Proteins 0.000 description 2
• DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 2
• 101710183280 Topoisomerase Proteins 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• 102000009618 Transforming Growth Factors Human genes 0.000 description 2
• 108010009583 Transforming Growth Factors Proteins 0.000 description 2
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
• 230000001594 aberrant effect Effects 0.000 description 2
• FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 238000001994 activation Methods 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 230000009824 affinity maturation Effects 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 229940100198 alkylating agent Drugs 0.000 description 2
• 239000002168 alkylating agent Substances 0.000 description 2
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
• 229940113720 aminosalicylate Drugs 0.000 description 2
• 239000003098 androgen Substances 0.000 description 2
• 230000000259 anti-tumor effect Effects 0.000 description 2
• 230000002155 anti-virotic effect Effects 0.000 description 2
• 239000003435 antirheumatic agent Substances 0.000 description 2
• 238000003782 apoptosis assay Methods 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 230000000740 bleeding effect Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 210000000601 blood cell Anatomy 0.000 description 2
• 230000036772 blood pressure Effects 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
• 239000002771 cell marker Substances 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
• 235000012000 cholesterol Nutrition 0.000 description 2
• 208000037976 chronic inflammation Diseases 0.000 description 2
• 230000006020 chronic inflammation Effects 0.000 description 2
• ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 238000002052 colonoscopy Methods 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• COFJBSXICYYSKG-OAUVCNBTSA-N cph2u7dndy Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 COFJBSXICYYSKG-OAUVCNBTSA-N 0.000 description 2
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 239000003405 delayed action preparation Substances 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 238000009510 drug design Methods 0.000 description 2
• 238000007876 drug discovery Methods 0.000 description 2
• 229940073621 enbrel Drugs 0.000 description 2
• 230000003628 erosive effect Effects 0.000 description 2
• 229930182833 estradiol Natural products 0.000 description 2
• 229960005309 estradiol Drugs 0.000 description 2
• 102000015694 estrogen receptors Human genes 0.000 description 2
• 108010038795 estrogen receptors Proteins 0.000 description 2
• 230000029142 excretion Effects 0.000 description 2
• 230000003325 follicular Effects 0.000 description 2
• 238000013467 fragmentation Methods 0.000 description 2
• 238000006062 fragmentation reaction Methods 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 229960003776 glatiramer acetate Drugs 0.000 description 2
• 208000035474 group of disease Diseases 0.000 description 2
• 230000035876 healing Effects 0.000 description 2
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
• 208000002672 hepatitis B Diseases 0.000 description 2
• 238000002657 hormone replacement therapy Methods 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• 230000008348 humoral response Effects 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 230000006058 immune tolerance Effects 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 239000003018 immunosuppressive agent Substances 0.000 description 2
• 229940125721 immunosuppressive agent Drugs 0.000 description 2
• 238000002650 immunosuppressive therapy Methods 0.000 description 2
• 230000008676 import Effects 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 238000011221 initial treatment Methods 0.000 description 2
• 238000007689 inspection Methods 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 210000000936 intestine Anatomy 0.000 description 2
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
• 238000009533 lab test Methods 0.000 description 2
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
• 229940040129 luteinizing hormone Drugs 0.000 description 2
• RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 229960004961 mechlorethamine Drugs 0.000 description 2
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
• 239000004005 microsphere Substances 0.000 description 2
• 210000001616 monocyte Anatomy 0.000 description 2
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
• 239000002105 nanoparticle Substances 0.000 description 2
• 230000021766 negative regulation of B cell proliferation Effects 0.000 description 2
• 230000001613 neoplastic effect Effects 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 210000004493 neutrocyte Anatomy 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
• 230000007310 pathophysiology Effects 0.000 description 2
• 201000001976 pemphigus vulgaris Diseases 0.000 description 2
• AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 229960005205 prednisolone Drugs 0.000 description 2
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 230000003449 preventive effect Effects 0.000 description 2
• 210000001948 pro-b lymphocyte Anatomy 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 230000002797 proteolythic effect Effects 0.000 description 2
• 229960004622 raloxifene Drugs 0.000 description 2
• 238000002708 random mutagenesis Methods 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• 229940127558 rescue medication Drugs 0.000 description 2
• GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 208000010157 sclerosing cholangitis Diseases 0.000 description 2
• 230000009291 secondary effect Effects 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 238000002864 sequence alignment Methods 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 238000011272 standard treatment Methods 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 239000004575 stone Substances 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 229940037128 systemic glucocorticoids Drugs 0.000 description 2
• 229960001967 tacrolimus Drugs 0.000 description 2
• 229960001603 tamoxifen Drugs 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• 229960001196 thiotepa Drugs 0.000 description 2
• XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
• 229960003087 tioguanine Drugs 0.000 description 2
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 201000002516 toxic megacolon Diseases 0.000 description 2
• 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 231100000397 ulcer Toxicity 0.000 description 2
• 230000036269 ulceration Effects 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 2
• 208000016261 weight loss Diseases 0.000 description 2
• 230000004580 weight loss Effects 0.000 description 2
• 229960004276 zoledronic acid Drugs 0.000 description 2
• NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
• JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
• YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
• XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
• HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
• CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
• WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• 150000000180 1,2-diols Chemical class 0.000 description 1
• FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
• 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
• FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
• PYTMYKVIJXPNBD-OQKDUQJOSA-N 2-[4-[(z)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 PYTMYKVIJXPNBD-OQKDUQJOSA-N 0.000 description 1
• RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
• BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
• NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
• GFGSZUNNBQXGMK-UHFFFAOYSA-N 2-chloro-4-nitrobenzamide Chemical compound NC(=O)C1=CC=C([N+]([O-])=O)C=C1Cl GFGSZUNNBQXGMK-UHFFFAOYSA-N 0.000 description 1
• YIMDLWDNDGKDTJ-QLKYHASDSA-N 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-QLKYHASDSA-N 0.000 description 1
• PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
• QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
• CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
• FXRYWOJYVGJZLE-UHFFFAOYSA-N 4,4-dimethyl-2,3-dihydro-1,2-benzoselenazine Chemical compound C1=CC=C2C(C)(C)CN[Se]C2=C1 FXRYWOJYVGJZLE-UHFFFAOYSA-N 0.000 description 1
• CNJLMVZFWLNOEP-UHFFFAOYSA-N 4,7,7-trimethylbicyclo[4.1.0]heptan-5-one Chemical compound O=C1C(C)CCC2C(C)(C)C12 CNJLMVZFWLNOEP-UHFFFAOYSA-N 0.000 description 1
• CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
• 102100022464 5'-nucleotidase Human genes 0.000 description 1
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
• BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
• XDBHURGONHZNJF-UHFFFAOYSA-N 6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C(OCC)C(OCC)=CC=C1C1=NC(C=2N=C(C=CC=2)C(O)=O)=CS1 XDBHURGONHZNJF-UHFFFAOYSA-N 0.000 description 1
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
• ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
• HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
• 206010000060 Abdominal distension Diseases 0.000 description 1
• 241000242759 Actiniaria Species 0.000 description 1
• 108010059616 Activins Proteins 0.000 description 1
• 102000005606 Activins Human genes 0.000 description 1
• ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
• 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
• PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
• PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
• 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 1
• CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
• 241000428352 Amma Species 0.000 description 1
• 108090000672 Annexin A5 Proteins 0.000 description 1
• 102000004121 Annexin A5 Human genes 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 206010002961 Aplasia Diseases 0.000 description 1
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
• 108010078554 Aromatase Proteins 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 244000003416 Asparagus officinalis Species 0.000 description 1
• 235000005340 Asparagus officinalis Nutrition 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 108091008875 B cell receptors Proteins 0.000 description 1
• 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
• 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
• 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 102100029945 Beta-galactoside alpha-2,6-sialyltransferase 1 Human genes 0.000 description 1
• DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
• 229940122361 Bisphosphonate Drugs 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 101000800130 Bos taurus Thyroglobulin Proteins 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
• 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 1
• 102100024220 CD180 antigen Human genes 0.000 description 1
• 101150013553 CD40 gene Proteins 0.000 description 1
• 108010084313 CD58 Antigens Proteins 0.000 description 1
• 102100027221 CD81 antigen Human genes 0.000 description 1
• 102100027217 CD82 antigen Human genes 0.000 description 1
• 102100035793 CD83 antigen Human genes 0.000 description 1
• 102000003922 Calcium Channels Human genes 0.000 description 1
• 108090000312 Calcium Channels Proteins 0.000 description 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 235000002566 Capsicum Nutrition 0.000 description 1
• SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
• AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 1
• JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
• 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
• 206010008803 Chromoblastomycosis Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 241000193403 Clostridium Species 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 206010071161 Colon dysplasia Diseases 0.000 description 1
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
• MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 208000014997 Crohn colitis Diseases 0.000 description 1
• 239000004971 Cross linker Substances 0.000 description 1
• 240000008067 Cucumis sativus Species 0.000 description 1
• 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
• XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
• NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
• 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
• 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
• CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
• 206010058314 Dysplasia Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 102000001301 EGF receptor Human genes 0.000 description 1
• 108060006698 EGF receptor Proteins 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 101150029707 ERBB2 gene Proteins 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
• OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
• 229940102550 Estrogen receptor antagonist Drugs 0.000 description 1
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
• DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
• 102100031511 Fc receptor-like protein 2 Human genes 0.000 description 1
• 102100031512 Fc receptor-like protein 3 Human genes 0.000 description 1
• 102100031513 Fc receptor-like protein 4 Human genes 0.000 description 1
• 102100031507 Fc receptor-like protein 5 Human genes 0.000 description 1
• 102100031508 Fc receptor-like protein 6 Human genes 0.000 description 1
• 241000724791 Filamentous phage Species 0.000 description 1
• MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
• 102000006395 Globulins Human genes 0.000 description 1
• 108010044091 Globulins Proteins 0.000 description 1
• JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 235000010469 Glycine max Nutrition 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102000006771 Gonadotropins Human genes 0.000 description 1
• 108010086677 Gonadotropins Proteins 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
• 102100031546 HLA class II histocompatibility antigen, DO beta chain Human genes 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 241000006746 Hemonia Species 0.000 description 1
• 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
• 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 1
• 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 1
• 101000863864 Homo sapiens Beta-galactoside alpha-2,6-sialyltransferase 1 Proteins 0.000 description 1
• 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
• 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 1
• 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
• 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 1
• 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
• 101000895818 Homo sapiens Chorionic somatomammotropin hormone 1 Proteins 0.000 description 1
• 101000956228 Homo sapiens Chorionic somatomammotropin hormone 2 Proteins 0.000 description 1
• 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
• 101000846911 Homo sapiens Fc receptor-like protein 2 Proteins 0.000 description 1
• 101000846910 Homo sapiens Fc receptor-like protein 3 Proteins 0.000 description 1
• 101000846909 Homo sapiens Fc receptor-like protein 4 Proteins 0.000 description 1
• 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 description 1
• 101000846906 Homo sapiens Fc receptor-like protein 6 Proteins 0.000 description 1
• 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
• 101000866281 Homo sapiens HLA class II histocompatibility antigen, DO beta chain Proteins 0.000 description 1
• 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
• 101001017833 Homo sapiens Leucine-rich repeat-containing protein 4 Proteins 0.000 description 1
• 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
• 101000984196 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 5 Proteins 0.000 description 1
• 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 description 1
• 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 description 1
• 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
• 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
• 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 1
• 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
• 108010000521 Human Growth Hormone Proteins 0.000 description 1
• 102000002265 Human Growth Hormone Human genes 0.000 description 1
• 239000000854 Human Growth Hormone Substances 0.000 description 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 238000012695 Interfacial polymerization Methods 0.000 description 1
• 108010005716 Interferon beta-1a Proteins 0.000 description 1
• 108010005714 Interferon beta-1b Proteins 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108090000177 Interleukin-11 Proteins 0.000 description 1
• 108010002386 Interleukin-3 Proteins 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 102000004388 Interleukin-4 Human genes 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 108010002335 Interleukin-9 Proteins 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
• XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
• 206010023804 Large intestine perforation Diseases 0.000 description 1
• 102100033304 Leucine-rich repeat-containing protein 4 Human genes 0.000 description 1
• 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
• 102100025574 Leukocyte immunoglobulin-like receptor subfamily A member 5 Human genes 0.000 description 1
• 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• MEPSBMMZQBMKHM-UHFFFAOYSA-N Lomatiol Natural products CC(=C/CC1=C(O)C(=O)c2ccccc2C1=O)CO MEPSBMMZQBMKHM-UHFFFAOYSA-N 0.000 description 1
• 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 241000282560 Macaca mulatta Species 0.000 description 1
• 239000004907 Macro-emulsion Substances 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
• 206010028116 Mucosal inflammation Diseases 0.000 description 1
• 102000007474 Multiprotein Complexes Human genes 0.000 description 1
• 108010085220 Multiprotein Complexes Proteins 0.000 description 1
• 208000005647 Mumps Diseases 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 101000846907 Mus musculus Fc receptor-like protein 5 Proteins 0.000 description 1
• 101000972289 Mus musculus Mucin-2 Proteins 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• 102100038610 Myeloperoxidase Human genes 0.000 description 1
• 108090000235 Myeloperoxidases Proteins 0.000 description 1
• 208000002033 Myoclonus Diseases 0.000 description 1
• OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
• OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
• MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
• OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
• MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• 230000004988 N-glycosylation Effects 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 102000003729 Neprilysin Human genes 0.000 description 1
• 108090000028 Neprilysin Proteins 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 102000007072 Nerve Growth Factors Human genes 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
• 208000011623 Obstructive Lung disease Diseases 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 1
• 102100037603 P2X purinoceptor 5 Human genes 0.000 description 1
• 101710189969 P2X purinoceptor 5 Proteins 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 241001504519 Papio ursinus Species 0.000 description 1
• 102000003982 Parathyroid hormone Human genes 0.000 description 1
• 108090000445 Parathyroid hormone Proteins 0.000 description 1
• 241000237988 Patellidae Species 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 102000015731 Peptide Hormones Human genes 0.000 description 1
• 108010038988 Peptide Hormones Proteins 0.000 description 1
• 241000042032 Petrocephalus catostoma Species 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 108010089430 Phosphoproteins Proteins 0.000 description 1
• 102000007982 Phosphoproteins Human genes 0.000 description 1
• 241000758706 Piperaceae Species 0.000 description 1
• 208000000474 Poliomyelitis Diseases 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 206010036105 Polyneuropathy Diseases 0.000 description 1
• 208000037062 Polyps Diseases 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 206010036774 Proctitis Diseases 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
• 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
• 101710109947 Protein kinase C alpha type Proteins 0.000 description 1
• 206010037549 Purpura Diseases 0.000 description 1
• 241001672981 Purpura Species 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
• 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 208000035415 Reinfection Diseases 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 102000016941 Rho Guanine Nucleotide Exchange Factors Human genes 0.000 description 1
• 108010053823 Rho Guanine Nucleotide Exchange Factors Proteins 0.000 description 1
• 101150054830 S100A6 gene Proteins 0.000 description 1
• CIEYTVIYYGTCCI-UHFFFAOYSA-N SJ000286565 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(O)C(=O)C2=C1 CIEYTVIYYGTCCI-UHFFFAOYSA-N 0.000 description 1
• 102100029216 SLAM family member 5 Human genes 0.000 description 1
• 239000002262 Schiff base Substances 0.000 description 1
• 150000004753 Schiff bases Chemical class 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 102100038081 Signal transducer CD24 Human genes 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
• 108010023197 Streptokinase Proteins 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• BXFOFFBJRFZBQZ-QYWOHJEZSA-N T-2 toxin Chemical compound C([C@@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@H]1[C@]3(COC(C)=O)C[C@@H](C(=C1)C)OC(=O)CC(C)C)O2 BXFOFFBJRFZBQZ-QYWOHJEZSA-N 0.000 description 1
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
• CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
• WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
• CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 1
• 206010043376 Tetanus Diseases 0.000 description 1
• 108010022394 Threonine synthase Proteins 0.000 description 1
• 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
• 102000036693 Thrombopoietin Human genes 0.000 description 1
• 108010041111 Thrombopoietin Proteins 0.000 description 1
• 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
• UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
• 206010054094 Tumour necrosis Diseases 0.000 description 1
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
• 208000037386 Typhoid Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 101150117115 V gene Proteins 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 241001516476 Vanda Species 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 241000863480 Vinca Species 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
• 206010000059 abdominal discomfort Diseases 0.000 description 1
• 229940028652 abraxane Drugs 0.000 description 1
• ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
• 229950002684 aceglatone Drugs 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000000488 activin Substances 0.000 description 1
• 229940037127 actonel Drugs 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 229960002964 adalimumab Drugs 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 208000021096 adenomatous colon polyp Diseases 0.000 description 1
• 102000019997 adhesion receptor Human genes 0.000 description 1
• 108010013985 adhesion receptor Proteins 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 230000004931 aggregating effect Effects 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 108010035879 albumin-bilirubin complex Proteins 0.000 description 1
• 108700025316 aldesleukin Proteins 0.000 description 1
• 229960002478 aldosterone Drugs 0.000 description 1
• OGSPWJRAVKPPFI-UHFFFAOYSA-M alendronate(1-) Chemical compound NCCCC(O)(P(O)(O)=O)P(O)([O-])=O OGSPWJRAVKPPFI-UHFFFAOYSA-M 0.000 description 1
• JMLGXYWHNOKLBE-HOTXNYTESA-A alicaforsen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 JMLGXYWHNOKLBE-HOTXNYTESA-A 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
• 150000008052 alkyl sulfonates Chemical class 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
• 229960002749 aminolevulinic acid Drugs 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 229960002932 anastrozole Drugs 0.000 description 1
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
• 229940030486 androgens Drugs 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000002280 anti-androgenic effect Effects 0.000 description 1
• 230000003092 anti-cytokine Effects 0.000 description 1
• 230000001142 anti-diarrhea Effects 0.000 description 1
• 229940046836 anti-estrogen Drugs 0.000 description 1
• 230000001833 anti-estrogenic effect Effects 0.000 description 1
• 230000000843 anti-fungal effect Effects 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000000051 antiandrogen Substances 0.000 description 1
• 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
• 229940125681 anticonvulsant agent Drugs 0.000 description 1
• 239000000729 antidote Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000013059 antihormonal agent Substances 0.000 description 1
• 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 208000002399 aphthous stomatitis Diseases 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
• 150000008209 arabinosides Chemical class 0.000 description 1
• 239000003886 aromatase inhibitor Substances 0.000 description 1
• 229940046844 aromatase inhibitors Drugs 0.000 description 1
• 150000004982 aromatic amines Chemical class 0.000 description 1
• 210000003567 ascitic fluid Anatomy 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 201000004339 autoimmune neuropathy Diseases 0.000 description 1
• 229940003504 avonex Drugs 0.000 description 1
• 210000002769 b effector cell Anatomy 0.000 description 1
• 229960004168 balsalazide Drugs 0.000 description 1
• IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 210000000270 basal cell Anatomy 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 229960003872 benzethonium Drugs 0.000 description 1
• FWLORMQUOWCQPO-UHFFFAOYSA-N benzyl-dimethyl-octadecylazanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 FWLORMQUOWCQPO-UHFFFAOYSA-N 0.000 description 1
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 229960002537 betamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
• 229940021459 betaseron Drugs 0.000 description 1
• QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
• 229960000997 bicalutamide Drugs 0.000 description 1
• 239000003613 bile acid Substances 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 239000003124 biologic agent Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 238000001815 biotherapy Methods 0.000 description 1
• 229950008548 bisantrene Drugs 0.000 description 1
• 150000004663 bisphosphonates Chemical class 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 238000011088 calibration curve Methods 0.000 description 1
• HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
• 229930195731 calicheamicin Natural products 0.000 description 1
• IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
• 229950009823 calusterone Drugs 0.000 description 1
• 229940112129 campath Drugs 0.000 description 1
• 229940088954 camptosar Drugs 0.000 description 1
• 230000005907 cancer growth Effects 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• 229960002115 carboquone Drugs 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 229930188550 carminomycin Natural products 0.000 description 1
• XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
• XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
• 229960003261 carmofur Drugs 0.000 description 1
• 229950001725 carubicin Drugs 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 210000004534 cecum Anatomy 0.000 description 1
• 229940047495 celebrex Drugs 0.000 description 1
• 229960000590 celecoxib Drugs 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000002032 cellular defenses Effects 0.000 description 1
• 229960005110 cerivastatin Drugs 0.000 description 1
• GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 229960003677 chloroquine Drugs 0.000 description 1
• WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• 229960002286 clodronic acid Drugs 0.000 description 1
• HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical compound [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 238000005354 coacervation Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 210000004953 colonic tissue Anatomy 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 231100000026 common toxicity Toxicity 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 229940124558 contraceptive agent Drugs 0.000 description 1
• 239000003433 contraceptive agent Substances 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 229940038717 copaxone Drugs 0.000 description 1
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
• 229960000258 corticotropin Drugs 0.000 description 1
• 229960004544 cortisone Drugs 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 229940109239 creatinine Drugs 0.000 description 1
• 238000009109 curative therapy Methods 0.000 description 1
• HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 229960000860 dapsone Drugs 0.000 description 1
• 238000013480 data collection Methods 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 229960005052 demecolcine Drugs 0.000 description 1
• 230000000779 depleting effect Effects 0.000 description 1
• 238000000151 deposition Methods 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
• 229950002389 diaziquone Drugs 0.000 description 1
• 239000012954 diazonium Substances 0.000 description 1
• 230000001079 digestive effect Effects 0.000 description 1
• PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
• 102000004419 dihydrofolate reductase Human genes 0.000 description 1
• 230000010339 dilation Effects 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
• 150000002009 diols Chemical class 0.000 description 1
• ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
• 229960000520 diphenhydramine Drugs 0.000 description 1
• 239000002988 disease modifying antirheumatic drug Substances 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
• 125000002228 disulfide group Chemical group 0.000 description 1
• 150000002019 disulfides Chemical class 0.000 description 1
• 150000004662 dithiols Chemical group 0.000 description 1
• AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
• 229930188854 dolastatin Natural products 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 229940115080 doxil Drugs 0.000 description 1
• 229950004203 droloxifene Drugs 0.000 description 1
• NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
• 229960004242 dronabinol Drugs 0.000 description 1
• 229950004683 drostanolone propionate Drugs 0.000 description 1
• 239000013583 drug formulation Substances 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
• 229950006700 edatrexate Drugs 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
• 238000001678 elastic recoil detection analysis Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 229940120655 eloxatin Drugs 0.000 description 1
• 150000002081 enamines Chemical class 0.000 description 1
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
• 229940095399 enema Drugs 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
• 229950010213 eniluracil Drugs 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
• 229960001904 epirubicin Drugs 0.000 description 1
• 230000001667 episodic effect Effects 0.000 description 1
• 230000009841 epithelial lesion Effects 0.000 description 1
• 229950002973 epitiostanol Drugs 0.000 description 1
• 229930013356 epothilone Natural products 0.000 description 1
• 150000003883 epothilone derivatives Chemical class 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
• 229950002017 esorubicin Drugs 0.000 description 1
• 229960001842 estramustine Drugs 0.000 description 1
• FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• 239000000328 estrogen antagonist Substances 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 229940009626 etidronate Drugs 0.000 description 1
• 229960005237 etoglucid Drugs 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 229940085363 evista Drugs 0.000 description 1
• 208000038004 exacerbated respiratory disease Diseases 0.000 description 1
• 229960000255 exemestane Drugs 0.000 description 1
• 229950011548 fadrozole Drugs 0.000 description 1
• 229940087861 faslodex Drugs 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 210000003608 fece Anatomy 0.000 description 1
• 229940087476 femara Drugs 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 230000003328 fibroblastic effect Effects 0.000 description 1
• 102000034240 fibrous proteins Human genes 0.000 description 1
• 108091005899 fibrous proteins Proteins 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 150000002222 fluorine compounds Chemical class 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 229960003765 fluvastatin Drugs 0.000 description 1
• 150000002224 folic acids Chemical class 0.000 description 1
• VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
• 235000008191 folinic acid Nutrition 0.000 description 1
• 239000011672 folinic acid Substances 0.000 description 1
• 229960004783 fotemustine Drugs 0.000 description 1
• YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
• 230000033581 fucosylation Effects 0.000 description 1
• 229960002258 fulvestrant Drugs 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 229940044658 gallium nitrate Drugs 0.000 description 1
• 229960002963 ganciclovir Drugs 0.000 description 1
• IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• 229940020967 gemzar Drugs 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229960002989 glutamic acid Drugs 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 150000002338 glycosides Chemical class 0.000 description 1
• 210000002175 goblet cell Anatomy 0.000 description 1
• XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
• 239000002622 gonadotropin Substances 0.000 description 1
• 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• 239000003966 growth inhibitor Substances 0.000 description 1
• 229960002706 gusperimus Drugs 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 125000005179 haloacetyl group Chemical group 0.000 description 1
• 235000015220 hamburgers Nutrition 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 208000035861 hematochezia Diseases 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 102000055229 human IL4 Human genes 0.000 description 1
• 102000057041 human TNF Human genes 0.000 description 1
• 230000009403 human autoimmunity Effects 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 229940048921 humira Drugs 0.000 description 1
• 230000004727 humoral immunity Effects 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 229940088013 hycamtin Drugs 0.000 description 1
• 229940057107 hydrocortisone enema Drugs 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 229920001477 hydrophilic polymer Polymers 0.000 description 1
• 229920001600 hydrophobic polymer Polymers 0.000 description 1
• 229960001330 hydroxycarbamide Drugs 0.000 description 1
• 229960004171 hydroxychloroquine Drugs 0.000 description 1
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
• 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• KNOSIOWNDGUGFJ-UHFFFAOYSA-N hydroxysesamone Natural products C1=CC(O)=C2C(=O)C(CC=C(C)C)=C(O)C(=O)C2=C1O KNOSIOWNDGUGFJ-UHFFFAOYSA-N 0.000 description 1
• 230000000544 hyperemic effect Effects 0.000 description 1
• 229940015872 ibandronate Drugs 0.000 description 1
• 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 210000003405 ileum Anatomy 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
• 229950008097 improsulfan Drugs 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 239000000893 inhibin Substances 0.000 description 1
• 108091008042 inhibitory receptors Proteins 0.000 description 1
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 229940124625 intravenous corticosteroids Drugs 0.000 description 1
• XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
• PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 244000145841 kine Species 0.000 description 1
• SIUGQQMOYSVTAT-UHFFFAOYSA-N lapachol Natural products CC(=CCC1C(O)C(=O)c2ccccc2C1=O)C SIUGQQMOYSVTAT-UHFFFAOYSA-N 0.000 description 1
• CWPGNVFCJOPXFB-UHFFFAOYSA-N lapachol Chemical compound C1=CC=C2C(=O)C(=O)C(CC=C(C)C)=C(O)C2=C1 CWPGNVFCJOPXFB-UHFFFAOYSA-N 0.000 description 1
• 239000008141 laxative Substances 0.000 description 1
• 229940125722 laxative agent Drugs 0.000 description 1
• 229940095570 lescol Drugs 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 229960003881 letrozole Drugs 0.000 description 1
• 229960001691 leucovorin Drugs 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 230000021633 leukocyte mediated immunity Effects 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 229950008325 levothyroxine Drugs 0.000 description 1
• 239000012669 liquid formulation Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 238000011866 long-term treatment Methods 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
• 229950008745 losoxantrone Drugs 0.000 description 1
• 229960004844 lovastatin Drugs 0.000 description 1
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 108010078259 luprolide acetate gel depot Proteins 0.000 description 1
• 229940087857 lupron Drugs 0.000 description 1
• RVFGKBWWUQOIOU-NDEPHWFRSA-N lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
• 229950002654 lurtotecan Drugs 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 229940099262 marinol Drugs 0.000 description 1
• 230000008774 maternal effect Effects 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 210000003519 mature b lymphocyte Anatomy 0.000 description 1
• 235000012439 matzos Nutrition 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 229960004296 megestrol acetate Drugs 0.000 description 1
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
• 229960001929 meloxicam Drugs 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 238000005374 membrane filtration Methods 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 1
• 229940099246 mevacor Drugs 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 229960005485 mitobronitol Drugs 0.000 description 1
• 229960003539 mitoguazone Drugs 0.000 description 1
• MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
• VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
• 229950010913 mitolactol Drugs 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 229960000350 mitotane Drugs 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 229940112801 mobic Drugs 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 238000002625 monoclonal antibody therapy Methods 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 230000002969 morbid Effects 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 208000010805 mumps infectious disease Diseases 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
• IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
• NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
• 239000002088 nanocapsule Substances 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 229940126617 natahzumab Drugs 0.000 description 1
• 229960005027 natalizumab Drugs 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 229940086322 navelbine Drugs 0.000 description 1
• MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 229960002653 nilutamide Drugs 0.000 description 1
• XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
• 229940085033 nolvadex Drugs 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 230000000269 nucleophilic effect Effects 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 230000000474 nursing effect Effects 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 230000002138 osteoinductive effect Effects 0.000 description 1
• 229940075461 other therapeutic product in atc Drugs 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
• 238000002638 palliative care Methods 0.000 description 1
• 229940046231 pamidronate Drugs 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 229960005489 paracetamol Drugs 0.000 description 1
• 244000045947 parasite Species 0.000 description 1
• 239000000199 parathyroid hormone Substances 0.000 description 1
• 229960001319 parathyroid hormone Drugs 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 229960001639 penicillamine Drugs 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 239000000813 peptide hormone Substances 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 210000001986 peyer's patch Anatomy 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 238000001050 pharmacotherapy Methods 0.000 description 1
• 238000009521 phase II clinical trial Methods 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
• 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
• NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
• 229960000952 pipobroman Drugs 0.000 description 1
• NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
• 229950001100 piposulfan Drugs 0.000 description 1
• 206010035485 plasmacytosis Diseases 0.000 description 1
• 238000002616 plasmapheresis Methods 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229940049548 pneumovax Drugs 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 230000007824 polyneuropathy Effects 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229940068977 polysorbate 20 Drugs 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 229940089484 pravachol Drugs 0.000 description 1
• VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 229940102535 prednisone 20 mg Drugs 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• 206010036784 proctocolitis Diseases 0.000 description 1
• 208000017048 proctosigmoiditis Diseases 0.000 description 1
• 230000003623 progesteronic effect Effects 0.000 description 1
• 230000005522 programmed cell death Effects 0.000 description 1
• 229940087463 proleukin Drugs 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 230000012743 protein tagging Effects 0.000 description 1
• 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
• UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 1
• 229960002185 ranimustine Drugs 0.000 description 1
• BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
• 229960000460 razoxane Drugs 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 238000013391 scatchard analysis Methods 0.000 description 1
• 238000004062 sedimentation Methods 0.000 description 1
• 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
• 229940124513 senna glycoside Drugs 0.000 description 1
• 230000035807 sensation Effects 0.000 description 1
• 229940048278 septra Drugs 0.000 description 1
• 230000000405 serological effect Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• 229940112726 skelid Drugs 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• 229960000999 sodium citrate dihydrate Drugs 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 229940074404 sodium succinate Drugs 0.000 description 1
• ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 229950006315 spirogermanium Drugs 0.000 description 1
• ICXJVZHDZFXYQC-UHFFFAOYSA-N spongistatin 1 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C ICXJVZHDZFXYQC-UHFFFAOYSA-N 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 229960004533 streptodornase Drugs 0.000 description 1
• 229960005202 streptokinase Drugs 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 229940014800 succinic anhydride Drugs 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 229960005404 sulfamethoxazole Drugs 0.000 description 1
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
• 229960001940 sulfasalazine Drugs 0.000 description 1
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
• 150000003461 sulfonyl halides Chemical class 0.000 description 1
• 229960000894 sulindac Drugs 0.000 description 1
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
• JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 238000009121 systemic therapy Methods 0.000 description 1
• FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
• 239000013076 target substance Substances 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
• 229940063683 taxotere Drugs 0.000 description 1
• 229960001674 tegafur Drugs 0.000 description 1
• WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 229960005353 testolactone Drugs 0.000 description 1
• BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 229940034208 thyroxine Drugs 0.000 description 1
• 229940019375 tiludronate Drugs 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 229960001017 tolmetin Drugs 0.000 description 1
• UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• 229960005026 toremifene Drugs 0.000 description 1
• XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 230000017105 transposition Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
• 229960000875 trofosfamide Drugs 0.000 description 1
• UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
• RXRGZNYSEHTMHC-BQBZGAKWSA-N troxacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)OC1 RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 description 1
• 229950010147 troxacitabine Drugs 0.000 description 1
• HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
• 229910052721 tungsten Inorganic materials 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 201000008297 typhoid fever Diseases 0.000 description 1
• 230000001562 ulcerogenic effect Effects 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 229940044953 vaginal ring Drugs 0.000 description 1
• 239000006213 vaginal ring Substances 0.000 description 1
• 229960002004 valdecoxib Drugs 0.000 description 1
• LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 229960001771 vorozole Drugs 0.000 description 1
• XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 230000036642 wellbeing Effects 0.000 description 1
• 229940053867 xeloda Drugs 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1
• 229940072168 zocor Drugs 0.000 description 1
• 229940002005 zometa Drugs 0.000 description 1